Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

June 15, 2017

Sarah Rutherford, MD, discusses rare DLBCL subtypes, ongoing research to improve outcomes for these patient populations, and the potential role of CAR T-cell therapy.

June 08, 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses risk factors for patients with early-onset colorectal cancer (CRC).

May 30, 2017

Peter Martin, MD, discusses the evolution of treatment and ongoing research for patients with mantle cell lymphoma.

May 23, 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).

May 15, 2017

John P. Leonard, MD, professor of medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the maintenance strategy of rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

May 12, 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the use of prognostic markers in the treatment of patients with chronic lymphocytic leukemia (CLL).

May 08, 2017

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

May 05, 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian, discusses preferences patients have for their treatment of mantle cell lymphoma (MCL).

May 05, 2017

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

May 02, 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer.

April 14, 2017

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.

April 11, 2017

Manish Shah, MD, discusses ongoing efforts to understand the distinction between early-onset CRC and traditional CRC.

April 06, 2017

David M. Nanus, MD, discusses evolving therapeutic strategies in the neoadjuvant and adjuvant setting for patients with renal cell carcinoma.

April 06, 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses indications of early-onset colorectal cancer (CRC).

January 30, 2017

Peter Martin, MD, discusses the efficacy of a combination regimen of ibrutinib and palbociclib in the treatment of patients with mantle cell lymphoma.

December 26, 2016

In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.

September 01, 2016

In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.

March 15, 2016

Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).

March 14, 2016

David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.

January 21, 2016

The FDA has approved carfilzomib (Kyprolis) in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed/refractory multiple myeloma following prior treatment with 1 to 3 lines of therapy